We are live on ! Find out more
HP

HealthInvest Partners Portfolio holdings

AUM $372M
1-Year Est. Return 59.89%
This Fund
S&P 500
This Quarter Est. Return
+3.3%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$47.3M
AUM Growth
+$3.96M
Cap. Flow
+$4.33M
Cap. Flow %
9.14%
Top 10 Hldgs %
100%
Holding
13
New
1
Increased
6
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
CAH icon
Cardinal Health
CAH
+$4.44M
2
BMY icon
Bristol-Myers Squibb
BMY
+$3.92M
3
GILD icon
Gilead Sciences
GILD
+$2.96M
4
VTRS icon
Viatris
VTRS
+$1.67M
5
MCK icon
McKesson
MCK
+$1.04M

Top Sells

Rank Stock Value
1
LJPC
La Jolla Pharmaceutical Company
LJPC
+$4.04M
2
HRMY icon
Harmony Biosciences
HRMY
+$3.71M
3
BIIB icon
Biogen
BIIB
+$3.26M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTMD icon
1
Utah Medical Products
UTMD
$223M
$7.34M 15.5%
86,000
– –
BMY icon
2
Bristol-Myers Squibb
BMY
$131B
$6.97M 14.72%
98,000
+54,000
+123% +$3.92M
GILD icon
3
Gilead Sciences
GILD
$162B
$6.48M 13.68%
105,000
+47,000
+81% +$2.96M
CI icon
4
Cigna
CI
$72.7B
$4.72M 9.96%
17,000
+3,000
+21% +$844K
ZVRA icon
5
Zevra Therapeutics
ZVRA
$705M
$4.68M 9.89%
750,000
+80,000
+12% +$453K
CAH icon
6
Cardinal Health
CAH
$55.7B
$4.67M 9.86%
+70,000
New +$4.44M
MCK icon
7
McKesson
MCK
$102B
$4.42M 9.33%
13,000
+3,000
+30% +$1.04M
VTRS icon
8
Viatris
VTRS
$19B
$4.09M 8.64%
480,000
+170,000
+55% +$1.67M
OPNT
9
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$2.26M 4.77%
210,000
– –
AUPH icon
10
Aurinia Pharmaceuticals
AUPH
$2.07B
$1.73M 3.65%
230,000
– –
BIIB icon
11
Biogen
BIIB
$30.5B
– –
-16,000
Closed -$3.26M
HRMY icon
12
Harmony Biosciences
HRMY
$2.26B
– –
-76,000
Closed -$3.71M
LJPC
13
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-1,265,000
Closed -$4.04M

Similar funds

KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
PAA
Peregrine Asset Advisers Portland, Oregon $371M AUM 41.36% 1-Year Est. Return
PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
PC
Prevatt Capital Nassau, Bahamas $371M AUM 9.39% 1-Year Est. Return

HealthInvest Partners's Q3 2022 Portfolio in Review

As of Q3 2022, HealthInvest Partners held 13 positions worth $47.3M, up 9.1% from $43.4M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

HealthInvest Partners deployed $4.33M of net new capital in Q3 2022, opening 1 new position and adding to 6 existing holdings. Its largest new stake was Cardinal Health: 70,000 shares worth $4.67M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the most notable exit was La Jolla Pharmaceutical Company, an estimated $4.04M sold.

  • HealthInvest Partners's largest Q3 2022 buy was Cardinal Health: 70,000 shares worth $4.67M.
  • HealthInvest Partners added most to Bristol-Myers Squibb in Q3 2022, an estimated $3.92M increase.
  • HealthInvest Partners fully exited La Jolla Pharmaceutical Company in Q3 2022, selling an estimated $4.04M.
  • HealthInvest Partners's ten largest holdings make up 100% of its $47.3M portfolio in Q3 2022.
  • HealthInvest Partners opened 1 new position and closed 3 in Q3 2022.
  • HealthInvest Partners's portfolio value rose 9.1% quarter-over-quarter to $47.3M.

Based on HealthInvest Partners's 13F filing for Q3 2022, filed 21 Oct 2022.